Solitary plasmacytoma (SP) is a rare clinical variant of malignant plasma cell proliferation; radiotherapy with or without local surgery is the treatment of choice. However, the disease progresses in a significant proportion of patients, requiring chemotherapy. The prognostic uncertainty is partly based on difficulties in disease monitoring. Tc99m-sestaMIBI is absorbed in various malignant tissues, including bone marrow in multiple myeloma lesions. We have investigated the ability of Tc99m-sestaMIBI scintigraphy to monitor patients with SP. Eight patients with SP were followed-up from June 1997 to May 2003. After induction treatment, which always included local procedures (surgery, radiotherapy), often followed by chemotherapy, the patients were monitored by physical examination, X-ray, CT scans, MRI, and biochemical parameters, at regular intervals. Tc99m-sestaMIBI scintigraphy was also performed repetitively in all patients. There was a strong correlation between standard procedures of follow-up and Tc99-sestaMIBI scan in 15/17 evaluations: tracer uptake was always normal in remission, decreased uptake was detected after partial remission and focal uptake was demonstrated in two patients at relapse. One false negative was observed at diagnosis and another during the follow-up. In this study, the sensitivity of Tc99m-sestaMIBI scintigraphy was 80%. The results of this study suggest that Tc99m-sestaMIBI scintigraphy is a useful tool for the follow-up of patients with SP.
|Number of pages||6|
|Publication status||Published - Jul 2004|
- Solitary plasmacytoma
ASJC Scopus subject areas